Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Cutting edge: Fc?RIII (CD16) and Fc?RI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma.

Cutting edge: Fc?RIII (CD16) and Fc?RI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma. J Immunol. 2012 Dec 15; 189(12):5513-7.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.